MHRA invites current and former suppliers to join Risk Ledger and complete a security profile to strengthen supply chain cyber security.
Similar Posts
Clinical trials for medicines: notifiable trials
Guidance on categorising certain clinical trials as ‘notifiable’.
Consultation on the Revised International Council for Harmonisation Guideline M4Q(R2)
The MHRA is consulting with UK stakeholders to gather feedback and comments on a revised international guideline, M4Q(R2).
Guidance: Pharmacovigilance following agreement of the Windsor Framework
Information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26
MHRA transactions over £500 made using the government procurement card (GPC).
Abrysvo▼ (Pfizer RSV vaccine) and Arexvy▼ (GSK RSV vaccine): be alert to a small risk of Guillain-Barré syndrome following vaccination in older adults
There is a small increase in the risk of Guillain-Barré syndrome following vaccination with Abrysvo (Pfizer respiratory syncytial virus (RSV) vaccine) and Arexvy (GSK RSV vaccine) in adults aged 60 years and older. Healthcare professionals should advise all recipients of Abrysvo and Arexvy that they should be alert to signs and symptoms of Guillain-Barré syndrome and, if they occur, to seek immediate medical attention as it requires urgent treatment in hospital.
Medicines: get scientific advice from MHRA
A summary of the types of scientific advice available at the MHRA, the process for getting advice and the fees involved.